Erythrocytosis / elevated hematocrit on Testosterone Cypionate: Week-by-Week Timeline of What to Expect

What is known about timing

Cypionate is an oil depot injected into muscle, and the Depo-Testosterone label gives a dose every 2 to 4 weeks and a half-life of about 8 days after injection [6]. The network meta-analysis pooled mean hematocrit change from placebo-controlled trials [1]. The 3-year review measured hematocrit at baseline and every 3 to 6 months [3]. A high reading can also reflect relative polycythemia from volume contraction rather than a true increase in red cell mass [8].

What was actually measured

Across 29 placebo-controlled randomized trials (3,393 men), every formulation raised mean hematocrit versus placebo: intramuscular enanthate/cypionate 4.0% (95% CI 2.9 to 5.1), oral testosterone undecanoate 4.3%, gel 3.0%, patch 1.4%, and intramuscular testosterone undecanoate 1.6% [1]. Enanthate/cypionate rose significantly more than patch; no other pair differed significantly [1].

In a retrospective review of 178 hypogonadal men followed for 3 years, hematocrit above 50% occurred in 66.7% of men on injectable testosterone, 12.8% on gels and 35.1% on pellets [3]. The injection group was younger (mean 42.5 versus about 54 years) with a higher starting hematocrit, and the review was not randomized [3]. A systematic review of drug-induced erythrocytosis likewise linked intramuscular formulations, higher doses and older age to higher risk, reporting erythrocytosis rates up to 66.7% in men on prescription testosterone and thromboembolic events in up to 2.7% [9].

Two reviews frame the overall risk: men on testosterone replacement had a 315% greater risk of erythrocytosis (hematocrit above 0.52) than controls, with all formulations raising hemoglobin and hematocrit and injectables doing so most [4], while short-acting injectables carry the highest reported incidence and the link to thromboembolic events remains unclear [5].

What the label says about monitoring

The Depo-Testosterone label (testosterone cypionate, intramuscular) states that androgens stimulate red blood cell production by enhancing production of erythropoietic stimulation factor, says to check hemoglobin and hematocrit periodically during long-term use, and notes that increased red cell mass may raise thromboembolic risk [6]. Polycythemia is among its listed adverse reactions [6]. The label also reports venous thromboembolism with testosterone products and says to discontinue treatment if a venous thromboembolic event is suspected [6].

The Endocrine Society guideline recommends against starting testosterone in men with an elevated hematocrit and recommends monitoring hematocrit during the first year of treatment [10].

When a high hematocrit becomes an action point

A 2023 clinical consultation guide states that providers should decrease or discontinue therapy if hematocrit exceeds 54%, until the hematocrit normalizes [2]. A 2022 review notes that the hematocrit cutoffs in current guidelines appear arbitrarily chosen and that evidence that secondary erythrocytosis causes harm during testosterone therapy is scarce [7]. Phlebotomy is described as an option considered for symptom control in elevated hematocrit [8] and as one of the interventions used in testosterone-associated erythrocytosis [7].

For medication details, see testosterone cypionate.